This pooled analysis of data from two phase 3, dedicated T2DM studies demonstrated that both dosing regimens of evolocumab consistently and effectively reduced ApoB and the cholesterol levels from ApoB-containing lipoproteins, as reflected by the reduction in non-HDL-C levels, across individuals with high TGs with and without AD. Here, APOB is linked to type 2 diabetes mellitus.